Abstracts

Skip to Late-Breaking Abstracts »

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).


Search word or phrase:

# Title Authors Category Keywords
O1 Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT Hólmfridur R. Halldórsdóttir, MSc; Lars Ringgaard, PhD; Martin Bak, PhD; Ditte Jæhger, MSc; Esben Christensen, MSc; Fredrik Melander, PhD; Mie L. Hübbe, MSc; Rasmus Eliasen, PhD; Frederikke P. Fliedner, MSc; Andreas Kjaer, MD, PhD; Anders E. Hansen, DVM, PhD; Jonas R. Henriksen, PhD; Thomas L. Andresen, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; TLR
O2 Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma Robyn Gartrell, MD; Andrew X. Chen, BS; Emanuelle M. Rizk, BA; Douglas K. Marks, MD; Margaret H. Bogardus, BA; Basil A. Horst, MD; Rui Chang, MD; Anthea Monod, PhD; Raúl Rabadán, PhD; Yvonne Saenger, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
O3 Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study. Sergio Rutella, MD, PhD, FRCPath; Jayakumar Vadakekolathu, PhD; Stephen Reeder, BS; Jenny Ashforth, Miss; Melissa Courtney, Miss; Amanda Coutts, PhD; Tressa Hood, MS; Sarah E. Church, PhD; Clare Coveney, PhD; Jan Davidson-Moncada, MD, PhD; Jorn Meinel, MD; Marc Schmitz, MD; Francesco M. Marincola, MD; Martin Bornhauser, MD; Sergio Rutella, MD, PhD, FRCPath; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune suppression; Leukemia/Lymphoma; Systems biology; Tumor microenvironment
P3 Predicting patient response to checkpoint blockade therapy using in vitro 3D cultures Kathryn Appleton, PhD; Ashley K. Elrod; Qi Jin Guo; Dennis Ruder; Tessa DesRochers, PhD; Tessa DesRochers, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Chemokine; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P4 Novel immune competent murine glioblastoma models derived from Nestin-CreERT2; QuakingL/L; P53L/L; PTENL/L mice Chao-Hsien Chen, MD; Renee Chin, MS; Genevieve P. Hartley, PhD; Cheng-En Hsieh, MD; Rishika Prasad, MS; Takashi Shingu, PhD; David S. Hong, MD; Jian Hu, PhD; Michael A. Curran, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Myeloid cells; MDSC; T cell; Tumor microenvironment
P5 Laminar Wash™ AUTO system: a reliable walk-away sample preparation solution for better TIL recovery without centrifugation Ira Kim; Melvin Lye; Roberta Zappasodi, PhD; Isabell Schulze; Christoph CE. Eberle, PhD; Chyan Ying Ke; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Taha Merghoub, PhD; Namyong Kim, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Clinical trial; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P6 Development of a peripheral blood mononuclear cells (PBMC) ImmunoGraft platform to evaluate the pharmacodynamics of Immuno-oncology therapeutics Bhavana Verma, PhD; Bruce Ruggeri; Amy Wesa, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Antigen presenting cells; Checkpoint blockade; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma; Vaccine
P7 Development of a Natural Killer (NK) ImmunoGraft Platform for the Evaluation of the Pharmacodynamics of Immuno-Oncology Therapeutics Bhavana Verma, PhD; Bruce Ruggeri; Jon Weidanz, PhD; Amy Wesa, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Checkpoint blockade; Immune monitoring; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P8 Monoclonal antibody detection from formalin-fixed paraffin-embedded tumor tissues using Fab-selective proteolysis nSMOL coupled with liquid chromatography and triple quadrupole mass spectrometry Takashi Shimada, PhD; Noriko Iwamoto, PhD; Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; John Cha; Brian Piening, PhD; Eric Tran, PhD; Hong-Ming Hu, PhD; Bernard Fox, PhD; William L. Redmond, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Tumor microenvironment
P9 Immune checkpoint biomarkers in hepatocellular carcinoma (HCC): Assessment of PD-L1 and tumour mutation burden in tumour samples from clinical patients Hisani Horne, PhD, MPH; Young S. Lee; Todd Creasy; Rebecca Fish; Jonathan Cairns; Paul Scorer; Janine Feng; Marietta Scott, PhD; Mark Gustavson; Aleksandra Dudek-Madej; Craig Barker; Nicholas Holoweckyi; Rebecca Halpin; Peiyi Wang; Quinea Lassiter; Xiaoling Xia; Mohammed Abdelwahab; Weimin Li; Alejandra Negro; Jill Walker; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immunoscore
P10 Inertial Microfluidics Enables Highly Consistent Separation and Concentration of Leukocytes from Human Peripheral Blood for Downstream B-Cell and T-Cell Functional Assays Sarah M. Mickool; Eric V. Smith; Aleksander J. Jonca; Gustavo Arnal; Mary Vincent Larcom; Melanie Scully; Peng Megn Kou, PhD; Nitin Kulkarni; Kyle C. Smith; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Immune monitoring; T cell
P11 Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks George A. Dominguez, PhD; John Roop; Alexander Aa. Polo, BS; Anthony Campisi, BS; Dmitry I. Gabrilovich, MD/PhD; Amit Kumar, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Clinical study; Immune monitoring; Myeloid cells; MDSC
P12 Deep characterization of the depleted plasma proteome in subjects with NSCLC using data independent acquisition mass spectrometry reveal host immune response mechanisms Nicholas Dupuis, PhD; Linda Sensbach; Sebastian Müller; Lukas Reiter; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Inflammation; Proteomics; Systems biology
P13 Immunomodulatory effects of Interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with Ziv-aflibercept Arjun Khunger, MD; Ghanashyam Sarikonda; Paul Frankel, PhD; Jenn Tsau, PhD; Zeni Alfonso, PhD; Jane Gao, MS; Anil Pahuja, BSc; Christine A. Vaupel, PhD; Naveen Dakappagari; Shabnam Tangri, PhD; Ahmad A. Tarhini, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell
P14 Validation of Dendritic Cell and Natural Killer Cell Signatures for Clinical Biomarker Development Bolan Linghu, PHD; Pei Zhang, PhD; Marylens Hernandez; Mingchao Xie, PhD; Christine Barbon; Srimathi Srinivasan; Deanna Russell, M.S.; Anna Coenen-Stass; Deanna A. Mele, PhD; Patricia McCoon, PhD; Jonathan Dry; Ben Sidders; Kris Sachsenmeier, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Dendritic cell; Gene expression; Immune monitoring; NK/NK T cell
P15 Microsatellite instability detection with cell-free DNA next-generation sequencing Ariane Lozac'hmeur, MS; Jason Perera, PhD; Denise Lau, PhD; Aly Khan, PhD; Ariane Lozac'hmeur, MS; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers
P16 Circulating immunological biomarkers for predicting response to neoadjuvant chemotherapy in TNBC patients Charlotte K. Milton, PhD; Thanussuyah Alaguthurai; Atousa khiabany, Mres; Sheeba Irshad, MD PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Biomarkers; Chemokine; Chemotherapy; Clinical study; Cytokine; Immune contexture; Immune monitoring; Solid tumors
P17 Role of plasma-derived exosome in monitoring immunotherapy response and toxicity Arnav Mehta, MD PhD; Gyulnara Kasumova; Alvin Shi; Lina Hultin Rosenberg; Emmett Sprecher; Dennie Frederick; Ryan J. Sullivan, MD; Keith T. Flaherty; Nir Hacohen; Genevieve M. Boland; Marijana Rucevic, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Proteomics; Solid tumors
P18 Liquid biopsy protein biomarkers to predict responses and elucidate resistance to cancer immunotherapy Arnav Mehta, MD PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Gyulnara Kasumova; Emmett Sprecher; Lina Hultin Rosenberg; Dennie Frederick; Ryan J. Sullivan, MD; Nir Hacohen; Keith T. Flaherty; Genevieve Boland; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics; Solid tumors
P20 Semaphorin 4D in peripheral blood of head and neck squamous cell carcinoma reads the histological pattern of tumor inflammation in real time Ioana Ghita; Manar Elnaggar; Risa Chaisuparat; John Papadimitriou; Joshua Lubek; Rania H. Younis, B.D.S., MDS., PhD; Soren M. Bentzen, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune monitoring; Inflammation; Tumor stroma
P21 Activation Profiling of tumor infiltrating CD8+ T cells reveals CTLA-4 mean fluorescence intensity correlates with response in treatment naïve melanoma. Lauren S. Levine, MD; Katy Tsai, MD; James C. Lee, MD; Clinton Wu, BS; Kelly Mahuron, MD; Alain Algazi, MD; Michael G. Rosenblum, MD PhD; Adil Daud, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P22 Transcriptomic Characterization of Immune Response within Diverse Tumor Environments using the NanoString® nCounter® PanCancer IO 360™ Assay Jessica Perez, PhD; Lei Yang; David Henderson, PhD; Heather A. Brauer, PhD; Sarah Warren, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Inflammation; Regulatory T cell (Treg cell); T cell; Tumor microenvironment
P23 High dimensional immune monitoring of peripheral blood samples from breast cancer patients using mass cytometry (CyTOF) Jose C. Villasboas, MD; Kaitlyn R. McGrath, M.S.; El-ad David Amir, PhD; Roberto A. Leon-Ferre, MD; Matthew P. Goetz, MD; Judy Boughey, MD; Jody Carter, MD, PhD; Krishna R. Kalari, PhD; Liewei Wang, MD, PhD; Vera J. Suman, PhD; Richard Weinshilboum, MD; Stephen M. Ansell, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Chemotherapy; Immune monitoring; Immune suppression; Immune tolerance; Myeloid cells; NK/NK T cell; Solid tumors
P24 Molecularly guided digital spatial profiling for highly multiplexed analysis of gene expression with spatial and single cell resolution Anushka Dikshit, PhD; Chris Merritt, PhD; Jamie Rose Kuhar; Karen Nyugen; Kristina Sorg; Bingqing Zhang; Courtney M. Anderson, PhD; Xiao-Jun Ma; Biomarkers, Immune Monitoring, and Novel Technologies Chemokine; Cytokine; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P25 A Conserved MART-1 T Cell Receptor Motif is Predictive of Responses to Checkpoint Blockade Ariel Y. Isser, BS.; Tatsuya Yoshida; Junya Ichikawa; Jeffrey S. Weber, MD, PhD; Jonathan P. Schneck, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors; T cell
P26 Murine T cell phenotype and function in a single-well format: a novel, multiplexed and high-throughput assay workflow using the iQue platform Veronica Bruce, PhD; Caroline Weldon; John O'Rourke; Veronica Bruce, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Cytokine; Immune contexture; Immune monitoring; Immune suppression; T cell
P27 Functional 3D-plEX quantitative multiplex immunofluorescence platform to assess IO drug impact on tumor microenvironment in ex vivo treated intact 3D-tumor organoids of fresh patient tumor tissue. Jenny Kreahling, PhD; Vijayendra Agrawal, PhD; Melba Page, PhD; Mibel Pabon, PhD; Soner Altiok, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Cytokine; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P28 Mass spectroscopy-based highly multiplexed super-resolution imaging method for fine details of tumor microenvironment monitoring and tumor-immune cell interactions Yunhao Bai, BS; Bokai Zhu; Michael Angelo, MD, PhD; Yongxin Zhao; Sizun Jiang, PhD; Xavier Rovira Clave, PhD; Garry P. Nolan, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Systems biology; T cell; Tumor microenvironment
P29 Comprehensive Image Analysis of Immunostained NSCLC Tissues Provides Necessary Context for Immune Oncology Biomarker Profiling Charles Caldwell, Jr., PhD; Jenifer Caldara, BS; Will Paces, BS; Kelsey Weigel, PhD; Roberto Gianani, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune contexture; Immune monitoring; Immune tolerance; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P30 Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors Sarah E. Church, PhD; Jason W. Reeves; Daniel R. Zollinger; Jill McKay-Fleisch; Andrew M. White, BSc; Michael D. Bailey; Arya Bahrami, PhD; Chris Merritt, PhD; Margaret Hoang; Sarah Warren, PhD; Joseph M. Beechem, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression; Immune contexture; Monocyte/Macrophage; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P31 Applying Multispectral Unmixing and Spatial Analyses to Explore Tumor Heterogeneity with a Pre-Optimized 7-color Immuno-Oncology Workflow Carla Coltharp, PhD; Bethany Remeniuk, PhD; Chichung Wang; Rachel Schaefer; Linying Liu; Glenn Milton; Victoria Duckworth; Michael McLane; Peter Miller; Yi Zheng; Carla Coltharp, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immunoscore; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P32 Differential immune contexture of human colorectal carcinomas with mismatch repair deficiency (MSI-H) and increased DNA damage responses (DDR). Shruti Desai, PhD; Venkata Nagineni; Micaela Morgada; Aravind N. Kalathil; Ila Datar; Charles Fuchs, MD, MPH; Patricia LoRusso, DO; Ranjit S. Bindra; Kurt A. Schalper, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P33 DNA damage response (DDR) is associated with increased adaptive anti-tumor responses and PD-L1 expression in human non-small cell lung cancer. Shruti Desai, PhD; Aravind N. Kalathil; Roy S. Herbst, MD, PhD; Ranjit S. Bindra; Patricia LoRusso, DO; Kurt A. Schalper, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
P34 A fully optimized end-to-end solution for I/O multiplex immunofluorescence staining using Opal Polaris 7-Color PD1/PD-L1 Panel Kits for lung cancer and melanoma Yi Zheng; Rachel Schaefer; Linying Liu; Glenn Milton; CARLA COLTHARP, PhD; Victoria Duckworth; Victoria Duckworth, MS; Michael McLane; Peter Miller, MS; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immunoscore; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P35 Pick-Seq®: a spatial analysis tool for immuno-oncology biomarker discovery utilizing multi-parameter imaging and RNA sequencing of tissue micro-regions Nolan Ericson; Rebecca Podyminogin; Jennifer Chow, PhD; Yu-An Chen; Jia-Ren Lin; Zoltan Maliga; Peter Sorger; Kyla Teplitz; Melinda R. Duplessis, PhD; Eric Kaldjian, MD; Tad George, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Biomarkers; Gene expression; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P36 The complexity of myeloid-derived suppressor cells in non-small cell lung cancer: A combinatorial multiplex IHC and flow cytometry approach Amanda Finan, PhD; Muriel Smet; Maroua Tliba; Manon Motte; Jean-Philippe Coton; Domenico Lazzaro; Renaud Burrer; Biomarkers, Immune Monitoring, and Novel Technologies MDSC; Tumor microenvironment
P37 ImmunoPET imaging of glioma-infiltrating myeloid cells using Zirconium-89-labeled anti-CD11b antibody Alexandra P. Foster, BS; Rajeev Kumar; Shubhanchi Nigam; Lauren McCarl; Robert S. Edinger; Ian Pollack; Carolyn Anderson; Wilson B. Edwards; Gary Kohanbash; Alexandra P. Foster, BS; Biomarkers, Immune Monitoring, and Novel Technologies Monocyte/Macrophage; Myeloid cells; MDSC; Pediatric tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P38 Sensitive methodologies for tracking T cell immunotherapy by MRI Brooke M. Helfer, PhD; Deanne Lister; Charles F. O'Hanlon III; Eric Ahrens; Brooke M. Helfer, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; CAR T cells; Solid tumors; T cell; T cell lineages
P39 Looking beyond the assay: Comparison of multiplex chromogenic and fluorescent immunohistochemistry for standardized immune oncology profiling in non-small cell lung carcinoma patients Ana Hidalgo Sastre, PhD; Lorenz Rognoni, PhD; Monika Baehner; Marco Testori; Jessica Chan; Andreas Spitzmüller; Nicolas Brieu, PhD; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Alex Haragan; John K. Field; Florian Leiss, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune contexture; Inflammation; Monocyte/Macrophage; T cell; Tumor microenvironment; Tumor stroma
P40 Tumour immunity signatures to expand current diagnostic approaches in mismatch repair deficient cancers in the context of Lynch Syndrome through InSituPlex technology and Tissue Phenomics integration Ryan A. Hutchinson, Fellow; Armin Meier, PhD; Bonnie Philips; Katir K. Patel, PhD; Sean R. Downing, PhD; Karan Sharma; Julia Como; Simin Daneshvar; Gillian Livock; Ingrid M. Winship; Christophe Rosty; Mark Jenkins; Gunter Schmidt; Daniel D. Buchanan; Ryan A. Hutchinson, Fellow; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune contexture; Immunoscore; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P41 Multiplexed Imaging for the simultaneous detection of nucleic acids and proteins to dissect the tissue immune landscape and microenvironment of viral diseases Sizun Jiang, PhD; Xavier Rovira Clave, PhD; Chi Ngai Chan, PhD; Bokai Zhu; Yunhao Bai, BS; Marc Bosse, PhD; David McIlwain, PhD; Sean C. Bendall, PhD; Michael Angelo, MD, PhD; Jacob Estes, PhD; Garry P. Nolan, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Leukemia/Lymphoma; Proteomics; Systems biology; T cell; Tumor microenvironment
P42 An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors Tyvette S. Hilliard; Nicholas Stavrou; Erinn Parnell; Judy Kuo; Eric Leones; Flora Sahafi; Josette William, PhD, MD; Sharon Stack; Anna Juncker-Jensen; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P43 A novel platform for highly multiplexed, single-cell imaging of cell suspensions Anum Khan; Won-Mean Lee; Jon Mulholland; Anum Khan; Dhananjay Wagh; John Coller; Gabriel Mercado; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Proteomics; T cell
P44 Solar-IHC: Cell-to-cell distances in the tumour immune microenvironment of Hepatocellular Carcinoma has the potential to prognosticate survival Matthew Leong, N.A.; Toh Han Chong; Choo Su Pin; Kiat Hon Lim Tony; Joycelyn Lee; David Wai; Poh Sheng Joe Yeong; Jin Miao Chen, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Cytokine; Immune contexture; Solid tumors; T cell; Tumor microenvironment
P45 Multiplex Immunofluorescence Staining, Whole Slide Imaging, and Spatial Phenotyping of T-cell Exhaustion, Regulatory T cells, and Myeloid-Derived Suppressor Cells in Tumor FFPE Samples Katherine lillard, PhD; Kyla Teplitz; Katir K. Patel, PhD; Michael Tomac, MS; Kate Lillard, PhD; Anne Hellebust, PhD; Mael Manesse, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; MDSC; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P46 Same-slide multiplex immunofluorescence and brightfield histological staining as a new research tool for fast and comprehensive pathology assessment of the tumor microenvironment Mael Manesse, PhD; Douglas Wood, PhD; Heike Boisvert, PhD; Sean R. Downing, PhD; Mael Manesse, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Immune contexture; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment; Tumor stroma
P47 Imaging cancer immunology: Systemic tracking of immune cells in vivo with magnetic particle imaging James R. Mansfield, Msc; Gang Ren; Jeff Gaudet; Yanrong Zhang; Sara N. Ghobadi; James R. Mansfield, Msc; Max Wintermark; Patrick Goodwill; Biomarkers, Immune Monitoring, and Novel Technologies Immune monitoring; Inflammation; Monocyte/Macrophage; Solid tumors
P48 Turning ‘cold’ tumours ‘hot’: Guided magnetic hyperthermia for tumour immune stimulation Patrick Goodwill; Daniel Hensley; Zhi Wei Tay; Elaine Yu; James R. Mansfield, Msc; James R. Mansfield, Msc; Blayne Kettlewell; Ryan Orendorff; Kyle Fields; Steve Conolly; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Immune adjuvant; Inflammation; Solid tumors; Tumor microenvironment
P49 Use of Ultivue InSituPlex® multiplex immunofluorescence to localize and quantify regulatory T lymphocytes in formalin-fixed paraffin-embedded human tissue sections Shawn P. O'Neil, DVM, PhD; Renee E. Huynh; Courtney Hebert; Jamie Buell; Sean R. Downing, PhD; John L. Jakubczak, PhD; Yutian Zhan, MS; Biomarkers, Immune Monitoring, and Novel Technologies Autoimmunity; Inflammation; Regulatory T cell (Treg cell); T cell; T cell lineages
P50 Rapid high-plex staining and simultaneous imaging for immunophenotyping of tissue sections Benjamin Pelz, PhD; Daniel Migliozzi; Diego G. Dupouy; Anne-Laure Leblond; Alex Soltermann; Martin AM. Gijs, Prof.; Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells; B cell; Biomarkers; Dendritic cell; Granulocyte; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P51 Phenotypic and Spatial Analysis of Inter- and Intra-tumor Heterogeneity Using Multiplexed Ion Beam Imaging (MIBI) Jason Ptacek, PhD; Robert Johnson, PH.D; Joann Palma, PH.D; Jay Tarolli; Rachel Finck; Murat Aksoy; Yi Zhang; Jessica Finn; Jason Ptacek, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P52 CyTOF in anti-ILT3 mAb drug discovery - humanized tumor model selection and in vivo PD/biomarker exploration Yujie Qu, MD; Alan Byford; Caniga Michael; Ying Huo; Barbara Joyce-Shaikh, BS.; Laurence Fayadat-dilman; Veronica Juan; Carl Mieczkowski; Laura Bald; Jeanne Baker; Michael Meehl; Scott Pruitt, MD, PhD; Stephen Alves; Lily Moy; Philip E. Brandish, PhD; Jie Zhang-Hoover; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune monitoring; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs)
P53 Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from IHC images Sripad Ram, PhD; Amy-Jackson Fisher; Pamela Whalen; Cory Painter; Pamela Vizcarra; Eric L. Powell, MD; Sripad Ram, PhD; Sripad Ram, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade
P54 Development of a 9-color immunofluorescence assay using tyramide signal amplification and multispectral imaging for high-throughput studies on FFPE tissue sections Bethany Remeniuk, PhD; Carla Coltharp, PhD; Kristin Roman, MS; Chichung Wang; Clifford C. Hoyt, MS; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P55 Combining the best of two worlds: Transfer of multiplex immunofluorescence images from non-small cell lung carcinoma patients into pseudo multiplex chromogenic immunohistochemistry images Lorenz Rognoni, PhD; Ana Hidalgo Sastre, PhD; Ana Hidalgo Sastre, PhD; Linda Brützel; Philipp Wortmann; Monika Baehner; Marco Testori; Jessica Chan; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Alex Haragan; John K. Field; Florian Leiss, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Carcinogenesis; Immune contexture; Inflammation; Monocyte/Macrophage
P56 Interrogating the effect of oncolytic Herpes simplex virus-1 on spatial arrangement of myeloid cells in glioblastoma multiforme using an ex vivo human system and multiplex immunohistochemistry Munisha Smalley, PhD; Misti Jain, PhD; Saravanan Thyiagarajan; Emily Alonzo; Katherine Crosby; Douglas Best; Hans Gertje, BS; Basavaraja U. Shanthappa; Ralph Pulchalski; Charles Cobbs; E. Antonio Chiocca; Sean Lawler, PhD; Aaron Goldman; Munisha Smalley; Biomarkers, Immune Monitoring, and Novel Technologies Dendritic cell; Immune monitoring; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P57 An ex-vivo human system elucidates a role for natural killer cells in the anticancer effect of drug combinations in triple negative breast cancer Aaron Goldman; Douglas Best; Saravanan Thiyagarajan; Misti Jain, PhD; Basavaraja U. Shanthappa; Munisha Smalley, PhD; Hans Gertje, BS; Aaron Goldman; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Immune suppression; Immune tolerance; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor stroma
P58 Brain MRI Performed within 4 Weeks of PD-1 Inhibitors as a Potential Prognostic Marker for Non-small Cell Lung Cancer (NSCLC) Ammar Sukari, MD; Misako Nagasaka, MD; Seongho Kim, PhD; Tahmida Chowdhury; Natasha Robinette, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade
P59 Highly Consistent automated multiplex immunofluorescence for immunoprofiling of solid tumors in clinical trials: assay validation study using multispectral imaging and digital analysis. Jaime Rodriguez-Canales, MD; Michael J. Surace, PhD; Lorenz Rognoni, PhD; Farzad Sekhavati; Andrew Fisher, PhD; Andreas Spitzmueller; Sara Batelli, PhD; Karma Dacosta; Vinay Pawar; Clifford Hoyt; Edwin R. Parra, MD., PhD; Jaime Rodriguez-Canales, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune contexture; Solid tumors
P60 Combining transcriptomic immune population inference with automated digital masking of H&E images finds immune effectors preferentially distribute within stroma regions Christopher W. Szeto, PhD; Mustafa Jaber, PhD; Liudmila Beziaeva; Kevin Kazmierczak; Steve Benz; Shahrooz Rabizadeh; Biomarkers, Immune Monitoring, and Novel Technologies MDSC; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma
P61 Segmentation and Classification of Single Cells using Multiplexed Ion Beam Imaging Jay G. Tarolli; Jay Tarolli; Jay Tarolli; Rachel Finck; Murat Aksoy; Yari Sigal; Noah Newgren; Jessica Finn; Jason Ptacek, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Biomarkers; T cell; Targeted therapy; Tumor microenvironment
P62 Bringing the tumor microenvironment into focus: Simplified development of seven-color multiplex immunohistochemistry-Immunofluorescence (mIF) panels Melissa Whiteman, PhD; Eric McIntush, PhD; Mike Spencer; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune monitoring; Tumor infiltrating lymphocytes (TILs)
P63 Clinical Assay Development and Validation of Multiplex Immunofluorescent (mIHC) Marker Panel for Evaluation of Tumor Infiltration Myeloid Cells in FFPE Tissue Sections Lan Yi, Ph.D; Jonathan Juco, MD; Ashhad Mahmood, MD; Omar F. Laterza; Charo Garrido; Lan Yi, Ph.D; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Granulocyte; Immune monitoring; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment
P64 Highly multiplexed single-cell spatial analysis of FFPE tumor tissues using CODEX® Jessica X. Yuan, PhD; Gajalakshmi Dakshinamoorthy; Joseph Kim; Sejal Mistry; Nadya Nikulina; Roya Bashier; Cassandra Hempel; Maria Elena Gallina; Julia Kennedy-Darling; Jessica X. Yuan, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Tumor microenvironment; Tumor stroma
P65 Mutation-Targeted T Cell Responses in Blood from Patients with Solid Tumors Prior to Treatment and which Evolve with Clinical Benefit from Anti-PD-1 Therapies Benjamin T. Yuen, PhD; Fangfang Yin, PhD; Duo An, PhD; Boi Quach; Linlin Guo, PhD; Joanne BL. Tan, PhD; Songming Peng, PhD; Zheng Pan, PhD; Olivier Dalmas, PhD; Robert Bao, PhD; Kyle Jacoby, PhD; Barbara Sennino, PhD; Stefanie J. Mandl, PhD; Matt Walters, PhD; Juan C. Jaen, PhD; Alex Franzusoff, PhD; Benjamin T. Yuen, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens
P66 A novel mass cytometry-based immunomonitoring platform for characterizing the peptide vaccine-induced immune response of HLA-A*0201+ patients with K27M+ diffuse midline gliomas Jared Taitt, BA; Payal Watchmaker, PhD; Takahide Nejo, MD, PhD; Neil Almeida; Kaori Okada; Sabine Mueller, MD PhD; Hideho Okada, MD, PhD; Jared Taitt, BA; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Clinical trial; Immune monitoring; Immune suppression; MDSC; Neoantigens; Pediatric tumors; T cell; Vaccine
P67 Use of a Regional Integrated Health Record Data Network to Identify Patients who Received Checkpoint Therapy Following Cancer Diagnosis as a Foundation for Exploring Immunotoxic Events Theresa Walunas, PhD; Carlos Galvez; Saya Jacob; Jeffrey A. Sosman, MD; Abel Kho; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Checkpoint blockade; Epidemiology; Immune toxicity
P68 Innate inflammatory pathways are associated with TIL growth and response to adoptive immunotherapy Suhendan Ekmekcioglu, PhD; Dai Ogata, MD, PhD; Caitlin Creasy, MS; Marie A. Forget, PhD; Sun-Hee Kim, PhD; Jason Roszik, PhD; Mike Spencer; Patrick Hwu, MD; Elizabeth A. Grimm, PhD; Chantale Bernatchez, PhD; Suhendan Ekmekcioglu, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Biomarkers; Immune suppression; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P69 Highly multiplexed single cell spatial analysis of the tumor microenvironment in lymphoma Monirath Hav, MD, PhD; Anthony Colombo; Erik Gerdtsson; Mohan Singh; Denaly Chen; Imran Siddiqi, MD PhD; James Hicks; Peter Kuhn, PhD; Akil Merchant, MD; Akil Merchant, MD; Biomarkers, Immune Monitoring, and Novel Technologies Immune contexture; Leukemia/Lymphoma; Tumor microenvironment
P70 Tissue-based characterization of T cell exhaustion in inflammatory bowel disease and colorectal cancer using multiplex IHC Marina Bleck, PhD; Diane Mierz; Ania Mikucki; Marie Marcher; Sidharth Kerkar, MD; Gerald Nabozny, PhD; Sean R. Downing, PhD; Alexander C. Klimowicz, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Autoimmunity; Biomarkers; Checkpoint blockade; Inflammation; T cell
P71 Refining tumor mutation burden values using variant expression Shannon T. Bailey, PhD; Muhammad Ekram, PhD; Jim Lund; Jeffrey R. Gulcher; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P72 Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms Dattatreya Mellacheruvu, PhD; Rachel Pyke; Charles Abbott, PhD; Nick Phillips; Rena McClory; John S. West, MBA; Richard Chen; Sean M. Boyle, PhD; Dattatreya Mellacheruvu, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Neoantigens; Proteomics; Vaccine
P73 Large scale multiomics reveals a marked bias in driver mutations toward areas not reliably presented to the immune system Alex S. Powlesland, PhD; Michael J. Cundell, PhD; Floriana Capuano, PhD; Brandon W. Higgs; David Lowne, BS; Ricardo J. Carreira, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Neoantigens; Proteomics; T cell; Targeted therapy; Tumor antigens
P74 Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patient compared to their tumor mutation burden Guilhem Richard, PhD; Randy F. Sweis, MD; Matthew Ardito, BA; Tzintzuni Garcia; Leonard Moise, PhD; Michael F. Princiotta, MS, PhD; Dominique Bridon; William Martin, BA MD; Gad Berdugo, MSc, MBA; Arjun Balar; Gary Steinberg; Anne S. de Groot, MD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Neoantigens; Regulatory T cell (Treg cell); T cell
P75 targetSCAPE and ultraSCAPE: Simultaneous identification and deep profiling of human antigen-specific T cells and other immune cell subsets by mass cytometry David Roumanes, PhD; Faris Kairi; Alessandra Nardin, DVM; Evan Newell, PHD; Michael Fehlings; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune monitoring; Neoantigens; T cell
P76 Development of immunopeptidomic platform for human leucocyte antigens class I using microflow liquid chromatography and quadrupole time-of-flight mass spectrometry Takashi Shimada, PhD; Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; John Cha; Brian Piening, PhD; Eric Tran, PhD; Hong-Ming Hu, PhD; Bernard Fox, PhD; William L. Redmond, PhD; Takashi Shimada, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune monitoring; Neoantigens; Proteomics; Tumor antigens
P77 Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms Charles Abbott, PhD; Eric Levy, PhD; Rachel Pyke; Rena McClory; Sekwon Jang, MD; Richard Z. Chen, PhD; Sean M. Boyle, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Neoantigens; T cell; Tumor microenvironment
P78 Optimization of Tumor Mutation Burden Measurement in FFPE DNA Janice K. Au-Young, PhD; Iris Casuga, PhD; Vinay Mittal; Dinesh Cyanam, MS; Elaine Wong-Ho; Fiona Hyland; Seth Sadis; Warren Tom, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors
P79 Molecular comparison of tumor microenvironment in primary lung, melanoma, and kidney tumors versus paired lung metastases reveals shared perturbations of the immune milieu during oligoprogression Davide Bedognetti, MD, PhD; Jessica Roelands, Master; Angelo Manfredi; Norma Maugeri; Francesca De Nicola; Ludovica Ciuffreda; Matteo Pallocca; Maurizio Fanciulli; Francesca Di Modugno, PhD; Paolo Visca; Barbara Antoniani; Gabriele Alessandrini; Darawan Rinchai, PhD; Wouter RL. Hendrickx, PhD; Paola Nistico', MD; Gennaro Ciliberto, MD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Immune contexture; Tumor infiltrating lymphocytes (TILs)
P80 HER2 is associated with prolonged survival in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade Carrie B. Brachmann, PhD; Emon Elboudwarej; Manish Shah, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Jingzhu Zhou; Dung Thai; Pankaj Bhargava; Daniel V. Catenacci, MD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment
P81 Association of tumor mutational burden with clinical, genomic, and treatment characteristics in advanced non-small cell lung cancer Connor Willis, PharmD; Hillevi Bauer, PharmD; Trang H. Au, PharmD; Sudhir Unni, PhD, MBA; Wallace Akerley, MD; Ashley Sekhon, MD; Firas Badin, MD; John L. Villano, MD, PhD; Matthew B. Schabath, PhD; Bing Xia, MD; Beth Gustafson, PharmD; Komal Gupte-Singh, PhD; Beata Korytowsky; John-michael Thomas, PharmD; Gabriel Krigsfield, PhD; Solomon J. Lubinga, PhD; diana brixner, PhD; David Stenehjem, PharmD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Solid tumors
P82 High-throughput pairing of single T-cell α and β chains along with phenotypic expression profiling Brittany Brown, BS; Miranda Byrne-Steele, PhD; Wenjing Pan, PhD; Song Li; Mary Eisenhower, BS; Daniel Weber; Mollye Depinet, MS; Xiahong Hou, PhD, MD; Alex Moore; Jian Han, MD PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Autoimmunity; CAR T cells; Gene expression; Immune monitoring; Immune tolerance; Regulatory T cell (Treg cell); T cell; T cell lineages; Targeted therapy
P83 Pan-cancer assessment of composite genomic biomarkers in immuno-oncology to predict responses and resistances to immune checkpoint inhibitor therapy Gustavo C. Cerqueira; Laurel A. Keefer; Kelly Gerding, PhD; Kenneth Valkenburg; Christina Oliveras; James R. White; Leila Ettehadieh; Christopher Gault; James Hernandez; Eric Kong; Isabell Loftin; Samuel Angiuoli; Abigail McElhinny; John K. Simmons, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Checkpoint blockade; Solid tumors; Tumor evasion
P84 Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers San-chi Chen, MD; Kien-Thiam Tan, PhD; Ming-Huang Chen; Yi-Ping Hung, MD; Yi-Lin Hsieh; Yi-Hua Jan; Yee chao; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Solid tumors
P85 Development of a pan-cancer NGS assay for detection of tumor mutational burden and targeted biomarkers from FFPE samples Dinesh Cyanam, MS; Vinay Mittal; Nickolay Khazanov; Paul Williams; Janice Au-Young; Gary Bee; Sameh El-Difrawy; Aren Ewing; Jennifer Kilzer; Anelia kraltcheva, Ph.D; Scott Myrand, MS; Yu-Ting Tseng; Cristina Van Loy; Elaine Wong-Ho; Chenchen Yang; Dinesh Cyanam, MS; Warren Tom, PhD; Santhoshi Bandla; Seth Sadis; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Immune monitoring; Solid tumors; Targeted therapy
P86 Predictive Immune Modeling enables biomarker discovery in NSCLC patients treated with second line immunotherapy Natalie A. LaFranzo, PhD; Steve Daniel, PhD; Walt Carney, PhD; Milan Bhagat; Natalie A. LaFranzo, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P87 All-in-One, quantitative immune repertoire profiling of PBMC and FFPE for renal cancer treatment evaluation Mollye Depinet, MS; Wenjing Pan, PhD; Sang-gin Wu, MD, PhD; Xiaohong Hou, MD PhD; Brittany Brown, BS; Mary Eisenhower, BS; Daniel Weber; Miranda Byrne-Steele, PhD; Michael Lotze; Jian Han, MD PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Autoimmunity; B cell; Cytokine; Immune monitoring; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
P88 Evaluation of a tumor-only pan-cancer targeted semi-conductor based next-generation sequencing (NGS) test for microsatellite instability in FFPE samples Sameh El-Difrawy, Ph. D; Anelia kraltcheva, Ph.D; Vinay Mittal; Elaine Wong-Ho; Dinesh Cyanam, MS; Seth Sadis; Jennifer Kilzer; Cristina Van Loy; Janice Au-Young, PhD; Aren Ewing; Sameh El-Difrawy; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Solid tumors
P89 Obesity related changes in AXL-driven inflammatory signaling impact survival in melanoma Alicia A. Gingrich, MD; Alexander Merleev, PhD; Kylie Abeson, BS; Robert Canter, MD, MAS, FACS; Emanual Maverakis; Amanda Kirane, MD; Alicia A. Gingrich, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression; Immune monitoring; Inflammation; Tumor microenvironment
P90 Unique tumor immune microenvironments of potentially PD-L1/TGF-β trap responsive tumors Sean T. Glenn, PhD; Sarabjot Pabla, MSc, PhD, BS; Erik Van Roey; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune contexture; Inflammation; Tumor microenvironment
P91 Expression profiling of T cells using nanoscale automation with a full-length RNA sequencing library preparation kit on a microfluidic circuit platform Thomas J. Goralski, PhD; Sangpen J. Chamnongpol; Michael J. Phelan; Jennifer Snyder-Cappione; Julie J. Alipaz; Joel J. Brockman; Brian J. Fowler; Jennifer A. Geis; Christopher J. Kubu; Raphael J. Kung; Benjamin J. Lacar; Naveen Ramalingam, PhD; Mandi Wong; Charles J. Park; David J. King; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression
P92 Survival Benefits of Comprehensive Genomic Profiling and Treatment in Metastatic Non-Small Cell Lung Cancer Alison Sexton Ward, PhD; Jennifer Johnson, MD; Komal Gupte-Singh, PhD; Mohammad Ashraf Chaudhary, PhD; Devender Dhanda, PhD; Oliver Diaz, PhD; Katherine Batt, MD, MSc; John Fox; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy
P93 The advanced immune-centric NGS cohort for colon cancer. Wouter RL. Hendrickx, PhD; Jessica Roelands, Master; Peter Kuppen; Francesco M. Marincola, MD; Najeeb Syed; Davide Bedognetti, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Gene expression; Immunoscore; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P94 A potential mechanism of anti-cancer immune response activated by immune-related adverse events (irAEs) in urological cancer patients Taigo Kato, MD, PhD; Motohide Uemura; Koji Hatano; Atsunari Kawashima; Takeshi Ujike; Kazutoshi Fujita; Kazuma Kioytani; Norio Nonomura; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; T cell; Tumor antigens
P95 Single-cell RNA-sequencing from clinically relevant core needle biopsies for evaluation of tumor-immune cell interactions in the tumor microenvironment Namit Kumar, PhD; Mohan Bolisetty; Peter Szabo, PhD; Xuan Li; Becky Penhallow; Ryan Golhar; Alice M. Walsh; Saumya Pant; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P96 T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome Eric Levy, PhD; Pamela Milani; Sean M. Boyle, PhD; Gabor Bartha; Charles Abbott, PhD; Robert Power; Rena McClory; Robin Li; John S. West, MBA; Richard Chen; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P97 TCRB repertoire convergence and clonal expansion define the NSCLC tumor microenvironment of responders to anti-PD-1 monotherapy Timothy Looney, PhD; Katharina Leonards; Ilaria Alborelli; Luca Quagliatta; Philip Jermann; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P98 Automated rarefaction analysis for precision human and mouse B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved specimens Timothy Looney, PhD; Geoffrey M. Lowman, PhD; Michelle Toro; Jayde Chang; Denise S. Topacio-Hall, BS, MA; Loni Pickle, PhD; Fiona Hyland; Timothy Looney, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Biomarkers; Immune monitoring; T cell; Tumor microenvironment
P99 TMBler: a bioinformatic tool for measuring and optimizing Tumor Mutational Burden quantification from targeted sequencing panels Laura Fancello; Luca Mazzarella, MD PhD; Alessandro Guida; Arnaud Ceol; Piergiuseppe Pelicci; Luca Mazzarella, MD PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Neoantigens
P100 Impact of obesity on immunity in gastroesophageal adenocarcinoma [GEAC] Sarbajit Mukherjee, MD, MS; Sami Ibrahimi; Yali Zhang; Jianmin Wang; Pawel Kalinski, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Solid tumors
P101 Immune-based classification of pleural malignant mesothelioma by using integrative transcriptome analysis. Ernest Nadal, MD, PhD; Ania Alay; David Cordero; Elisabeth Aliagas; José C. Ruffinelli; Ramón Palmero; Ricard Ramos; Ivan Macía; Anna Ureña; Fran Rivas; Xavier Solé; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P102 CT antigens are frequently expressed non-inflamed tumors Sarabjot Pabla, MSc, PhD, BS; Erik Van Roey; Sean T. Glenn, PhD; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Gene expression; Immune contexture; Neoantigens; Tumor microenvironment; Tumor stroma
P103 Detection of human leukocyte antigen class I loss of heterozygosity in solid tumor types by next-generation DNA sequencing Jason Perera, PhD; Brandon Mapes, PhD; Denise Lau, PhD; Ameen Salahudeen; Aly Khan, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells; Bioinformatics; Biomarkers; Tumor evasion
P104 Impact of chemotherapy (chemo) on peripheral T-cell diversity and implications for subsequent immunotherapy response in breast cancer Joanna Pucilowska, PhD; Paul Fields, PhD; Valerie K. Conrad, BS; David B. Page, MD; Alison K. Conlin, MD; Joanna Pucilowska, PhD; Catherine Sanders, PhD; Raina A. Tamakawa, MS; Brie M. Chun, MD; Isaac K. Kim, MD; Mark Schmidt; Biomarkers, Immune Monitoring, and Novel Technologies Chemotherapy; Clinical study; Immune monitoring; T cell
P105 PD-L1 isoform as a potential biomarker to predict response for anti-PD-(L)1 treatment Kunbin Qu, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Tumor evasion
P106 Tumor Mutational Burden profile (TMB) of Oncogenic Driver Mutations in Non Small Cell Lung Cancer Nitika Sharma; Paul R. Walker, MD; Nitika Sharma; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; Targeted therapy
P107 Changes in tumor mutational burden in serially biopsied non-small cell lung cancer James W. Smithy, MD, MHS; David H. Hwang, MD; Yvonne Li; Liam Spurr; Andrew D. Cherniack, PhD; Lynette M. Sholl; Mark Awad, MD PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Solid tumors
P108 Working Towards Precision Medicine of the Tumor Microenvironment Kristen Strand-Tibbitts, PhD; Kyung Kim, PhD; Jeeyun Kim; Seung-Tae Kim; Jung-Yong Hong; Laura Benjamin; Kristen Strand-Tibbitts, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Solid tumors; Targeted therapy; Tumor microenvironment
P109 Predictive performance of a CD8-derived signature by gene expression profiling in patients with urothelial carcinoma from CheckMate 275 Peter Szabo, PhD; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Robin H. Edwards, PhD; Saumya Pant; Abdel Saci; Neeraj Adya; Matthew D. Galsky, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell
P110 Tumor CD8+ T-cell infiltration assessed by gene expression profiling alone or by immunohistochemistry plus epithelial-mesenchymal transition gene expression in urothelial carcinoma in CheckMate 275 Peter Szabo, PhD; Abdel Saci; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Scott D. Chasalow; Michael Montalto; Robin H. Edwards, PhD; Saumya Pant; Neeraj Adya; Bruce Fischer, MD; Matthew D. Galsky, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell
P111 Clinical and Immunologic Implications of a Microsatellite Instability Score in Lung Cancer Pedro Viveiros, MD; Misuk Lee; Bhoomika Sukhadia, MD; Kyunghoon Rhee; Victor Wang; Jeffrey Chuang; Young Kwang Chae, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immunoscore; Neoantigens; Solid tumors
P112 A new way of immunity exploration by linking highly multiplexed antigen recognition to immune repertoire and phenotype Dagmar Walter, PhD; Stephane C. Boutet; Michael JT. Stubbington, PhD; Katherine A. Pfeiffer; Josephine Y. Lee; Luz Montesclaros; Julia K. Lau; Daniel P. Riordan; Alvaro Martinez Barrio; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Antibody; Biomarkers; Gene expression; Genetic polymorphism; T cell; T cell lineages
P113 Dynamic analysis and visualization of the immune infiltration in human cancer by integrating TCGA data Mingchao Xie, PhD; Bolan Linghu, PHD; Zhongwu Lai, PhD; Jonathan Dry; Ben Sidders; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Immune contexture; Immunoscore; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P114 TISSUTAL IMMUNE PROFILE AND PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE BREAST CANCER. Andrea Botticelli, MD; Bruna Cerbelli; Simone Scagnoli; Maria Ida Amabile; Alessandro De Luca; Lucio Fortunato; Leopoldo Costarelli; Marianna Nuti, PhD; Giulia D'Amati; Paolo Marchetti; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Chemotherapy; Immune adjuvant; Immune suppression; Immunoscore; Tumor microenvironment
P115 Deep proteomic characterization of FFPE tumor samples from late-stage melanoma subjects treated with anti-PD-1 immunotherapy Nicholas Dupuis, PhD; Jakob Vowinckel, PhD; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele; Antonio Sorrentino; Vito Vanella; Daniel Heinzmann; Paolo Antonio A. Ascierto, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Systems biology
P116 Centrifuge-free red blood cell lysis and immunostaining of whole blood for flow cytometry using Laminar Wash™ system Ira Kim; Melvin Lye; Chyan Ying Ke; Nadiezda Fernandez Oropeza; Sigeeta Rajaram; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Namyong Kim, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune suppression; Metabolism; NK/NK T cell; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P117 Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project Florence Monville, PhD; Frederic Vely; Joseph Ciccolini; Florence Sabatier; Stephane Garcia; Vanina Leca; Marion Fabre; Christelle Piperoglou; Pernelle Outters; Laurent Arnaud; Laurent Vanhille, PhD; Caroline Lauge, BA; Anna Martirosyan, Dr; Aurelie Collignon; Marie Roumieux; Julien Mazieres; Maurice Perol; Françoise Dignat-George; Eric Vivier; Fabrice Barlesi, MD, PhD; Jacques Fieschi, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune contexture; Immune monitoring; Immunoscore; MDSC; Tumor infiltrating lymphocytes (TILs)
P118 HYDRA platform development to investigate Siglec-engaging tumor immunosuppressive glyco-codes Li Peng, PhD; Adam Petrone; Adam Shoemaker; Jillian Prendergast, PhD; Zakir Siddiquee; Jenny Che; Lihui Xu, BS; Karl Normington, PhD, MBA; James Broderick; Li Peng, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Tumor evasion; Tumor microenvironment
P119 Analytical validation of run-to-run and site-to-site performance of a human immune profiling assay and automated data analysis solution for CyTOF mass cytometry technology Clare Rogers, MS Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Granulocyte; Immune contexture; Immune monitoring; Myeloid cells; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs)
P120 Evaluation of CD8 score by automated quantitative image analysis in metastatic melanoma treated with PD1 blockade: preliminary results Anjali Rohatgi, MD PhD; Douglas Hartman; Arivarasan Karunamurthy; Julie Burkette; Yana G. Najjar, MD; John M. Kirkwood, MD; Hassane M. Zarour, MD; Liron Pantanowitz; Diwakar Davar, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P121 Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture Thomas Sbarrato, PhD; Laurent Vanhille, PhD; Mounia Filahi; Anna Martirosyan, Dr; Véronique Frayssinet; Caroline Davin, BA; Caroline Laugé; Assil Benchaaben; Alboukadel Kassambara; Felipe Guimaraes; Régis Perbost; Jérôme Galon; Hélène Girardi; Jacques Fieschi, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune contexture; Immune suppression; Immunoscore; Monocyte/Macrophage; MDSC; Regulatory T cell (Treg cell); Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P122 Microfluidic-based Cell Separation Method Improves Workflow for Evaluation of Rare Lymphocytes from Cancer Patient Samples Jodi Stone, BS.; Megan E. Nichols, AAS in Biotechnology; Amy Austin; Kala Bradshaw; Jessica E. Norris, BS, MT; Jennifer Montague, PhD; Peng Meng Kou, PhD; Nitin Kulkarni; Nirav Sheth; Anya Manning, MBA; Sarah M. Mickool; Kyle C. Smith; Ravi Kapur; John D. Powderly, II, MD, CPI; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Immune monitoring; T cell
P123 Identification of mRNA signatures that predict response to immunotherapy in melanoma patients Ioannis A. Vathiotis, MD; Amy Sullivan; Sarah Warren, PhD; Nicole Gianino; Sandra Martinez-Morilla, PhD; Pok Fai Wong, MD, MPhil; Harriet Kluger, MD; Konstantinos N. Syrigos; David L. Rimm, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Gene expression; Inflammation; NK/NK T cell; Tumor microenvironment
P124 A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Claire Gormley; Biomarkers, Immune Monitoring, and Novel Technologies T cell; Targeted therapy
P125 ADENOSINE AND AMP GENE EXPRESSION PROFILES PREDICT RESPONSE TO ADENOSINE PATHWAY THERAPIES AND INDICATE A NEED FOR DUAL BLOCKADE OF CD73 AND A2AR WITH CD73 INHIBITORS. Stephen Willingham, PhD; Drew Hotson, PhD; Jessica Hsieh; Brian Munneke; Long Kwei, PhD; Joseph J. Buggy; Richard A. Miller, MD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune suppression; MDSC; Solid tumors; T cell; Tumor evasion; Tumor microenvironment
P126 Discovery of biomarkers associated with benefit from PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling Jon Zugazagoitia, MD; Swati Gupta, PhD; Kit Fuhrman, MS PhD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; NK/NK T cell; T cell
P127 Development of a 12-marker immunofluorescence multiplex panel for the in-depth investigation of the tumor immune landscape analyzing 4,096 phenotypes Courtney Hauck; Aditi Sharma; Monique Johnson; Wenya Yang; Bonnie Phillips, PhD; Mark Burton, HTL ASCP; Douglas Wood, PhD; Stephanie Hennek, PhD; Mael Manesse, PhD; J Kent Moore, PhD; Katir K. Patel, PhD; Jamie Buell; Sean R. Downing, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Bioinformatics; Biomarkers; Immune contexture; Monocyte/Macrophage; NK/NK T cell; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P128 Pooled analysis of Programmed Death Factor Ligand 1 (PD-L1) expression as a predictive biomarker using individual data on 7,918 randomized study patients Andrea Arfe; Geoffrey Fell; Brian Alexander, MD MPH; Mark Awad, MD PhD; Scott J. Rodig, MD, PhD; Lorenzo Trippa; Jonathan Schoenfeld, MD, MPH; Jonathan Schoenfeld, MD, MPH; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Clinical study; Solid tumors
P129 Correlation of circulating CD8 T cell activation with response to immunotherapy in advanced renal cell carcinoma Jennifer Carlisle, MD; Caroline S. Jansen, BS; Adriana M. Reyes; Nataliya Prokhnevska, BS; Deborah Baumgarten, MD; Viraj A. Master, MD, PhD; R. Donald Harvey, PharmD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Mehmet A. Bilen; Haydn T. Kissick; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell
P130 Melanoma patients harbor pre-existing IgG autoantibodies targeting neuronal proteins that associate with differential clinical outcomes following checkpoint blockade Tyler Hulett, PhD; Michael Gowen, MD; Keith Giles; Danny Simpson; Jeremy Tchack; Una Moran; Zarmeena Dawood; Anna C. Pavlick, MD, MBA; Shaohui Hu; Hua Zhong; Michelle Krogsgaard; Tomas Kirchhoff, PhD; Iman Osman; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Proteomics; Tumor antigens
P131 Single cellular interrogation of tumor microenvironment enables diagnosis and prognostication of malignancies Wei Jian Tan; Jian Hang Lam; Mona Meng Wang; Paola Ricciardi-Castagnoli; Anita Sook Yee Chan; Tony Kiat Hon Lim; Joe Poh Sheng Yeong; Tong Seng Lim, PhD; Biomarkers, Immune Monitoring, and Novel Technologies B cell; Biomarkers; Clinical study; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P132 Harmony: Integrative tool to analyse and visualise Multiplex-Immunofluorescence Single-Cell Data Duoduo Wu; Joe P. Yeong, MBBS, PhD; Grace S. Tan; Marion Chevrier; Josh J. Loh; Tony K. Lim; Jinmiao Chen; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Tumor microenvironment
P133 High tumor expression of DKK1 is associated with improved clinical benefit and longer progression free survival across multiple solid tumors when treated with a targeted anti-DKK1 antibody (DKN-01) Michael Kagey, PhD; Girish Naik, MD; Michael Haas, PhD; Heidi Heath; Franziska Schurpf-Huber; Walter Newman, PhD; Cynthia Sirard, MD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; NK/NK T cell; Solid tumors
P134 Prognostic value of tumor microenvironment based on PD-L1 expression and CD8+ TILs density in locally advanced NSCLC treated with concurrent chemoradiotherapy Lukas Kaesmann, MD; Kathrin Gennen; Julian Taugner; Chukwuka Eze; Monika Karin; Olarn Roengvoraphoj; Jens Neumann; Amanda Tufman; Michael Orth; Simone Reu; Claus Belka; Biomarkers, Immune Monitoring, and Novel Technologies Chemotherapy; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P135 Studying Loss of Y chromosome in colorectal and prostate cancers in males for non-invasive cancer biomarkers AMBREEN ASIM, PhD; Sarita Agarwal; Rakesh Kapoor; Neeraj Rastogi; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers
P136 Quantitative/spatial analysis of Tregs reveal a prominent biomarker role in human non-small cell lung cancer (NSCLC) Richa Gupta, BS; Nicolas Rodriguez-Arriagada; Shruti Desai, PhD; Konstantinos N. Syrigos; Roy S. Herbst, MD, PhD; Vamsidhar Velcheti, MD FACP; David L. Rimm, MD, PhD; Sarah B. Goldberg, MD, MPH; Kurt A. Schalper, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs)
P137 Development and high specification validation of a recombinant rabbit monoclonal antibody to accurately detect human PD-L2 expression in FFPE tissue sections by immunohistochemistry Simon Renshaw; Will Howat, PhD; Subham Basu, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Biomarkers; Checkpoint blockade; Immunoscore; Proteomics; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P138 Review of evidence for predictive value of microsatellite instability/mismatch repair status in response to non-anti-PD-(L)1 therapies in patients with advanced or recurrent endometrial cancer Cara Mathews, MD; Ellie Im; Liliana Alfaya; Cara Mathews, MD; Cara Mathews, MD; Karin Travers; Craig Gibson; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Chemotherapy; Targeted therapy
P139 Expression of GITR and GITR-L by Head and Neck Squamous Cell Cancer Rachna L. Moudgil, MS; Christopher C. Paustian, PhD; Carmen Ballesteros-Merino, PhD; Shawn M. Jensen, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Carlo B. Bifulco, MD; Marcus A. Couey, MD, DDS; Traci L. Hilton, PhD; Bernard A. Fox, PhD; Rom Leidner, MD; R. Bryan Bell, DDS, MD; Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells; Costimulation; Immune contexture; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; Tumor stroma
P140 Myeloid cell contexture and IL-8 expression as a candidate immunotherapy target in Non-Small Cell Lung Cancer (NSCLC). Venkata Vamsi Nagineni, MD; Kurt A. Schalper, MD, PhD; Shruti Desai, PhD; Ignacio Melero, MD; Miguel F. Sanmamed, MD, PhD; Richa Gupta; Roy S. Herbst, MD, PhD; Venkata Vamsi Nagineni, MD; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Chemokine; Granulocyte; Targeted therapy; Tumor microenvironment; Tumor stroma
P141 One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining Harsha A. Ranganath, MD; Amit Jain; Justin R. Smith; Julie Ryder; Amina Chaudry; Emily Miller; Felicia Hare; Poojitha Valasareddy; Rob Seitz; David R. Hout; Brock L. Schweitzer; Tyler J. Nielsen; Janice Mullins; Gregory Vidal; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P142 Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer (NSCLC) using EpiSwitchTM epigenetic profiling Parantu Shah, PhD; Ewan Hunter; Shobha Potluri; Sen Zhang; Mehrnoush Dezfouli; Jennifer Back; Louis James; Navin Jandor; Ryan Powell; Matthew Salter; Aroul Ramadass; Jayne Green; Willem Westra; Haidong Dong, MD, PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Alexandre Akoulitchev; Ti Cai; Paul B. Robbins; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy
P143 Development and Validation of Baseline Predictive Biomarkers for Response to Immuno-Checkpoint Treatments in the Context of Multi-line and Multi-Therapy Cohorts using EpiSwitchTM epigenetic profiling. Parantu Shah, PhD; Ewan Hunter; Shobha Potluri; Sen Zhang; Mehrnoush Dezfouli; Jennifer Back; Louis James; Navin Jandor; Ryan Powell; Matthew Salter; Aroul Ramadass; Jayne Green; Willem Westra; Haidong Dong, MD, PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Alexandre Akoulitchev; Ti Cai; Paul B. Robbins; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy
P144 Quantification of tumor-stroma-immune contexture by multiplex fluorescent immunohistochemistry and whole-slide digital image analysis Adriana Racolta, PhD; Mehrnoush Khojasteh, PhD; Jennifer Giltnane; Antony Hubbard, BS; Hongjun Zhang; Miriam Matei; Jessica Baumann; Wenjun Zhang, MD, PhD; Tsu-Shuen Tsao, PhD; Hartmut Koeppen; Lisa Ryner; Xingwei Wang; Jim Martin; Auranuch Lorsakul; Ilya Ravkin; Smadar Shiffman; Lidija Pestic-Dragovich; Lei Tang, PhD; Yulei Wang, BA PhD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P851 Identifying potential predictive biomarkers from plasma exosomes and adoptive T cells that differentiate short and long-term metastatic nasopharyngeal cancer survivors treated with chemotherapy and virus-specific T cells Timothy Shuen, Who-Whong WANG, PhD, Han Chong Toh, MBBChir, Janice Lim, Cherlyn Tan, Jennie Kosasih, Rachael Cheong Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Biomarkers; Gene expression; Solid tumors; T cell
P852 Transcriptomic analysis of dysfunctional CD8+ TILs in melanoma identifies bile acid and MTOR pathways as novel potential immunotherapy targets Cheryl Cameron, PhD, Brian Richardson, Jackelyn Golden, Lukas Pfannensttiel, Michael Cartwright, Yousef Moustafa, Samjhana Thapaliya, Gustavo Roversi, Yee Peng Phoon, Mark Cameron, Brian Gastman, MD, Cheryl Cameron, PhD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P853 Single Cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients Chuan Li, Yee Peng Phoon, Keaton Karlinsey, Ye Tian, Samjhana Thapaliya, Lili Qu, Mark Cameron, Cheryl Cameron, PhD, Antoine Menoret, Pauline Funchain, MD, Jung-Min Song, RN, CNS, C. Marcela Diaz-Montero, Annabelle Rodriguez, Christopher Bonin, Anthony Vella, Beiyan Zhou, Brian Gastman, MD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment